Adverse reactions to treatment and subsequent dosage adjustment
| Adverse effects | N (%) | Dosage reduction | Discontinuation |
| Musculoskeletal | 2 (6%) | 0 | 0 |
| Myalgia | 1 (3%) | 0 | 0 |
| Arthralgia | 1 (3%) | 0 | 0 |
| General | 2 (6%) | 0 | 0 |
| Tiredness | 1 (3%) | 0 | 0 |
| Fatigue | 1 (3%) | 0 | 0 |
| Gastrointestinal | 19 (61%) | 4 (13%) | 7 (23%) |
| Non-specific gastrointestinal disturbances | 6 (19%) | 0 | 1 (3%) |
| Dyspepsia | 1 (3%) | 0 | 0 |
| Aerophagy | 1 (3%) | 0 | 0 |
| Abdominal pain | 6 (19%) | 2 (6%) | 3 (10%) |
| Nausea | 9 (29%) | 2 (6%) | 6 (19%) |
| Vomiting | 3 (10%) | 0 | 3 (10%) |
| Diarrhoea | 4 (13%) | 3 (10%) | 1 (3%) |
| Constipation | 1 (3%) | 1 (3%) | 0 |
| Heartburn | 1 (3%) | 1 (3%) | 0 |
| Cutaneous | 5 (16%) | 0 | 2 (6%) |
| Phototoxicity | 3 (10%) | 0 | 1 (3%) |
| Exanthema | 1 (3%) | 0 | 1 (3%) |
| Pruritus | 1 (3%) | 0 | 0 |
| Psychiatric | 2 (6%) | 0 | 0 |
| Insomnia | 1 (3%) | 0 | 0 |
| Moodiness | 1 (3%) | 0 | 0 |
| Central nervous system | 2 (6%) | 1 (3%) | 0 |
| Headache | 1 (3%) | 0 | 0 |
| Dizziness | 1 (3%) | 1 (3%) | 0 |